These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7047353)

  • 1. Effect of granulocyte proteases on human coagulation factors IX and X. The protective effect of calcium.
    Kárpáti J; Váradi K; Elödi S
    Hoppe Seylers Z Physiol Chem; 1982 May; 363(5):521-5. PubMed ID: 7047353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of human Factor VIII by granulocyte proteases.
    Váradi K; Marossy K; Asbóth G; Elödi P; Elödi S
    Thromb Haemost; 1980 Feb; 43(1):45-8. PubMed ID: 6773173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant mechanism of factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis.
    Ishikawa M; Kumashiro M; Yamazaki Y; Atoda H; Morita T
    J Biochem; 2009 Jan; 145(1):123-8. PubMed ID: 18977769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
    Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
    Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased resistance of factor IXa-factor VIII complex against inactivation by granulocyte proteases.
    Váradi K; Elõdi S
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):571-8. PubMed ID: 6777896
    [No Abstract]   [Full Text] [Related]  

  • 6. Does inflammatory proteolytic activity contribute to the increased factor IX activation peptide in men at high risk of coronary heart disease? A preliminary study.
    Miller GJ; Bauer KA; Howarth DJ; Mitchell JP; Cooper JA
    Thromb Haemost; 2002 Mar; 87(3):415-20. PubMed ID: 11916072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa.
    Panteleev MA; Saenko EL; Ananyeva NM; Ataullakhanov FI
    Biochem J; 2004 Aug; 381(Pt 3):779-94. PubMed ID: 15104540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and sequence characterization of coagulation factor IX/factor X-binding protein from the venom of Echis carinatus leucogaster.
    Chen YL; Tsai IH
    Biochemistry; 1996 Apr; 35(16):5264-71. PubMed ID: 8611513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of platelet surface bound factors IXa and VIII against specific inhibitors.
    Váradi K; Elödi S
    Thromb Haemost; 1982 Feb; 47(1):32-5. PubMed ID: 6978548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood coagulation factor IX/factor X-binding proteins with anticoagulant activity].
    Atoda H; Morita T
    Rinsho Byori; 1989 Apr; Spec No 81():75-81. PubMed ID: 2754813
    [No Abstract]   [Full Text] [Related]  

  • 11. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition.
    Kolkman JA; Mertens K
    Biochem J; 2000 Sep; 350 Pt 3(Pt 3):701-7. PubMed ID: 10970782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa.
    Scandura JM; Walsh PN
    Biochemistry; 1996 Jul; 35(27):8903-13. PubMed ID: 8688426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Direct proteolysis of coagulation factors through granulocyte enzymes as a possible mechanism of blood coagulation disorders in acute leukemia and septicemia].
    Egbring R; Schmidt W; Havemann K
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1629-32. PubMed ID: 1030064
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling human zymogen factor IX.
    Perera L; Darden TA; Pedersen LG
    Thromb Haemost; 2001 Apr; 85(4):596-603. PubMed ID: 11341491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor IX activation by factor XIa proceeds without release of a free intermediate.
    Wolberg AS; Morris DP; Stafford DW
    Biochemistry; 1997 Apr; 36(14):4074-9. PubMed ID: 9100000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein.
    Atoda H; Ishikawa M; Mizuno H; Morita T
    Biochemistry; 1998 Dec; 37(50):17361-70. PubMed ID: 9860851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance.
    He X; Shen L; Malmborg AC; Smith KJ; Dahlback B; Linse S
    Biochemistry; 1997 Mar; 36(12):3745-54. PubMed ID: 9132028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro mutagenesis study of two critical glutamic acids in the calcium binding loop of the factor IX heavy chain.
    Hamaguchi N; Stafford D
    Thromb Haemost; 1994 Dec; 72(6):856-61. PubMed ID: 7740454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of coagulation factors IX and X to the endothelial cell surface.
    Heimark RL; Schwartz SM
    Biochem Biophys Res Commun; 1983 Mar; 111(2):723-31. PubMed ID: 6404275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-EGF monoclonal antibody that detects intramolecular communication in factor IX.
    Persson KE; Knobe KE; Stenflo J
    Biochem Biophys Res Commun; 2001 Sep; 286(5):1039-44. PubMed ID: 11527405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.